Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTRB1 | P17538 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 2/20 | 0.50 |
| ▸ | TGM2 | P21980 | 1/20 | 0.50 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | CTSK | P43235 | 2/20 | 0.48 |
| ▸ | TACR1 | P25103 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14769904 | 1.00 | CTRB1 (0.54) | CTRB1LMNASMN1; SMN2ATMTGM2 | |
| SCHEMBL7372388 | 0.91 | CTRB1 (0.54) | CTRB1LMNASMN1; SMN2ATMTGM2 | |
| SCHEMBL8173806 | 0.91 | CTRB1 (0.54) | CTRB1LMNASMN1; SMN2ATMTGM2 | |
| SCHEMBL930561 | 0.88 | MBOAT4 (0.58) | CTRB1LMNASMN1; SMN2ATMMBOAT4 | |
| SCHEMBL22747610 | 0.88 | MBOAT4 (0.58) | CTRB1LMNASMN1; SMN2ATMMBOAT4 | |
| SCHEMBL17280899 | 0.88 | ALDH1A1 (0.53) | CTRB1LMNASMN1; SMN2ATMMBOAT4 | |
| SCHEMBL930559 | 0.88 | MBOAT4 (0.58) | CTRB1LMNASMN1; SMN2ATMMBOAT4 | |
| SCHEMBL3930093 | 0.86 | CTRB1 (0.55) | CTRB1LMNASMN1; SMN2ATMHTT | |
| SCHEMBL3930095 | 0.86 | CTRB1 (0.55) | CTRB1LMNASMN1; SMN2ATMHTT | |
| SCHEMBL8232784 | 0.86 | MBOAT4 (0.51) | CTRB1LMNASMN1; SMN2ATMMBOAT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043629-B2 | RIP1K inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| WO-2023194895-A1 | PYRROL DERIVATIVES AS INHIBITORS OF APOLIPOPROTEIN L-1 | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-10-12 | — | — | WO | disclosed |
| US-20230227469-A1 | RIP1K INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2023-07-20 | — | — | US | disclosed |
| CN-115867548-A | RIP1K inhibitors | 里格尔药品股份有限公司 | 2023-03-28 | — | — | CN | disclosed |
| US-11584758-B2 | RIP1K inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| EP-4126864-A1 | RIP1K INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2023-02-08 | — | — | EP | disclosed |
| EP-3897833-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | Vertex Pharmaceuticals Incorporated (US) | 2021-10-27 | — | — | EP | disclosed |
| US-20210317135-A1 | RIP1K INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2021-10-14 | — | — | US | disclosed |
| WO-2021203011-A1 | RIP1K INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2021-10-07 | — | — | WO | disclosed |
| WO-2020131807-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584758-B2 | RIP1K inhibitors | RIPK1, RIPK2, RIPK3 | CTRB1 2891/4885LMNA 2114/4885SMN1; SMN2 1932/4885 |
| US-12043629-B2 | RIP1K inhibitors | RIPK1, RIPK2, RIPK3 | CTRB1 2891/4885LMNA 2114/4885SMN1; SMN2 1932/4885 |
| US-20210317135-A1 | RIP1K INHIBITORS | RIPK1, RIPK2, RIPK3 | CTRB1 2891/4885LMNA 2114/4885SMN1; SMN2 1932/4885 |
| US-20230227469-A1 | RIP1K INHIBITORS | RIPK1, RIPK2, RIPK3 | CTRB1 2891/4885LMNA 2114/4885SMN1; SMN2 1932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.